



DF/HCC Breast and Gynecologic Cancer Symposium

Friday, March 29, 2024
Joseph B. Martin Conference Center
Harvard Medical School
77 Avenue Louis Pasteur
Boston, MA 02115

SUSAN F. SMITH
CENTER FOR
WOMEN'S CANCERS

- 7:15 am** **Sign-In, Continental Breakfast, Poster Set-Up**
- 8:00 am** **Welcome/Purpose of Symposium**
Susan F. Smith Center Leaders
- 8:10 am** **J. Dirk Iglehart, M.D., Visiting Scholar Lecture**
Harnessing omics and AI for precision breast oncology
Christina Curtis, PhD, MSc
RZ Cao Professor of Medicine, Genetics & Biomedical Data Science
Director AI and Cancer Genomics
Director, Breast Cancer Translational Research
Investigator, Chan Zuckerberg Biohub
Stanford University
(35-40 min talk, 10 mins questions)
- 9:00 am** **SESSION I: Genomics**
Chair: Gerburg Wulf
- 9:00 – 9:45 am 3 oral presentations (10 mins each; 5 mins questions)
- Abstract #1 Okoh Frimpong: Chemoproteomic Evaluation of PROTACs Targeting Estrogen Receptor Alpha in ER+ Breast Cancer
- Abstract #4 Zheqi Li: KDM4C histone demethylase prevents histone cleavage in breast cancer
- Abstract #9 Jessica St. Laurent: Shifted assembly and function of mSWI/SNF family subcomplexes underlie targetable dependencies in endometrioid carcinomas
- 9:45 am** **POSTER SESSION**
9:45 am – 10:30 am – Open Posters
- 10:30 am** **SESSION II: Risk, Prevention & Disparities/Clinical**
Chair: Sara Tolaney
- 10:30 – 11:15 am 3 oral presentations (10 mins each; 5 mins questions)
- Abstract #12 Haohui Duan: BRCA2 haploinsufficiency induces P53 degradation in primary mammary epithelial cells – a crucial early event in breast tumor promotion
- Abstract #18 Jennifer Mongiovi: Associations between intrauterine device use and ovarian cancer risk among 11 population-based case-control studies
- Abstract #21 Xingping Qin: Safely targeting endogenous and therapy-enhanced BCL-XL dependence in ovarian cancer using the PROTAC DT2216

11:15 am

M. Patricia Cronin Memorial Lecture

Why listening to women matters in ovarian cancer research

Sarah M. Temkin, M.D.

Associate Director for Clinical Research

Office of Research on Women's Health

Office of the Director, NIH

(35-40 min talk, 10 mins questions)

12:05 pm

Lunch and Open Posters

12:05 – 1:15pm

1:15 pm

SESSION III: Drug Resistance/Animal Models

Chair: Patricia Donahoe

1:15 – 2:15 pm

4 oral presentations (10 mins each; 5 mins questions)

Abstract #30

Carman Li: Brca1 haploinsufficiency promotes early tumor onset and epigenetic alterations in a mouse model of hereditary breast cancer

Abstract #32

Yusuke Matoba: Targeting Bcl-XL is a potential novel therapy for uterine serous cancer

Abstract #35

Ramya Ravindranathan: PARG inhibitor sensitivity is correlated with accumulation of single strand DNA gaps in preclinical models of ovarian cancer

Abstract #40

Ting Liu: Intratumoral heterogeneity drives resistance to Antibody Drug Conjugate therapy: Analysis of the NeoSTAR trial of neoadjuvant Sacituzumab govitecan for localized TNBC.

2:15 pm

SESSION IV: Tumor Microenvironment/Immunology

Chair: Jean Zhao

2:15 – 3:00 pm

3 oral presentations (10 mins each; 5 mins questions)

Abstract #41

Sara Busatto: Breast cancer-derived extracellular vesicles modulate the endocytic metabolism and morphodynamics of the endothelial cells of the blood-brain barrier

Abstract #43

Maeva Chauvin: Targeting Follistatin-like 3 to reverse immunotherapy resistance in ovarian cancer

Abstract #46

Adam Nelson: Immune mediated mechanisms of PARPi resistance in BRCA1-associated triple negative breast cancer (TNBC)

3:00 pm

Announcement of Awards and Adjourn